Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acarbose formulation crossover study in type 2 diabetes
ChiCTR2000038346Phase 4Not yet recruiting
- Sponsor
- Central Hospital Affiliated to Shandong First Medical University
- Start
- Sep 2020
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of acarbose in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Central Hospital Affiliated to Shandong First Medical University. Primary endpoints: Postprandial plasma glucose fluctuation and Safety. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
acarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000038346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038346.